CTI BIOPHARMA CORP
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | |
|---|---|---|---|---|---|---|
| Revenue | $53.9M | $0 | $0 | $3.3M | $26.3M | $25.1M |
| Operating income | −$79.8M | −$95.3M | −$47.8M | −$40.7M | −$32.9M | −$39.5M |
| Net income | −$93.0M | −$97.9M | −$52.5M | −$40.0M | −$29.3M | −$40.7M |
| Total assets | $125.9M | $72.4M | $58.2M | $46.3M | $89.8M | $54.9M |
| Total liabilities | $143.5M | $68.7M | $18.2M | $28.4M | $36.9M | $38.8M |
| Equity | −$17.6M | $3.8M | $40.0M | $23.7M | $58.7M | $21.8M |
| EPS (diluted) | $-0.81 | $-1.09 | $-0.74 | — | — | $-0.71 |
| Shares out. | 99.9M | 76.7M | 73.7M | 58.0M | 58.0M | 28.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- −147.9%
- Net margin
- −172.4%
- Return on equity
- 529.1%
- Return on assets
- −73.8%
- Return on capital (ROCE)
- −178.2%
- Liabilities / assets
- 114.0%
- Debt / equity
- —
- Book value / share
- $-0.18
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- -68.65distress
- Accruals / assets
- −9.4%clean
- Piotroski F-Score
- 4/8mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 4 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Debt acceleration / triggering event · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsJun 26, 2023
- Other material eventMay 30, 2023
- Entered a material agreement · Amended charter or bylaws · Other material eventMay 10, 2023
- Results of operationsMar 6, 2023
- Results of operationsNov 7, 2022
- Director / officer changeOct 13, 2022
- Other material eventSep 28, 2022
- Other material eventAug 15, 2022
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.